Download Full Text (647 KB)
Neonatal abstinence syndrome (NAS) is a condition affecting newborns exposed to an opioid in utero. Symptoms of NAS include excessive crying, poor feeding, and disordered autonomic control. Up to 2/3 of infants will require pharmacologic therapies to reach symptom control. Opioids including morphine and methadone are the current first-line treatments. Buprenorphine is being investigated as a treatment of NAS. The purpose of this analysis was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of BUP in infants with NAS.
Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome
Pharmacy and Pharmaceutical Sciences
Moore, PharmD, Jason N.; Gastonguay, Marc; Adeniyi-Jones, MD, Susan C.; Moody, David E.; and Kraft, MD, FACP, Walter K., "Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome" (2017). Department of Pharmacology and Experimental Therapeutics Posters. 4.